MannKind | MNKD - Des Atouts





Des Atouts Changement Date
Adma Biologics USD 665.18M 40.94M 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Insmed USD 2.08B 188.7M 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
MacroGenics USD 217.87M 38.97M 2026-03
MannKind USD 744.4M 47.78M 2026-03
Merck USD 128.68B 8.18B 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Novavax USD 1.04B 133.35M 2026-03
Novo Nordisk DKK 76.18B 412.98B 2025-06
Pfizer USD 207.62B 542M 2026-03
Sanofi EUR 128.02B 1.22B 2026-03
Xencor USD 736.85M 138.65M 2026-03